Functional Epistatic Interaction between rs6046G>A in F7 and rs5355C>T in SELE Modifies Systolic Blood Pressure Levels

Said El Shamieh1, Ndeye Coumba Ndiaye1, Maria G. Stathopoulou1, Helena A. Murray2, Christine Masson1, John V. Lamont2, Peter Fitzgerald2, Athanase Benetos3,4, Sophie Visvikis-Siest1,4*

1 Université de Lorraine, “Génétique Cardio-vasculaire”, EA-4373, Nancy, France, 2 Randox Laboratories Ltd, Crumlin, Antrim, United Kingdom, 3 INSERM U961, Université de Lorraine, Nancy, France, 4 CHU Nancy, Brabois, Service de Gériatrie, Nancy, France

Abstract

Background: Although numerous genetic studies have been performed, only 0.9% of blood pressure phenotypic variance has been elucidated. This phenomenon could be partially due to epistatic interactions. Our aim was to identify epistatic interaction(s) associated with blood pressure levels in a pre-planned two-phase approach.

Methods and Results: In a discovery cohort composed of 3,600 French individuals, we found rs6046A allele in F7 associated with decreased blood pressure levels ($P_1=3.7 \times 10^{-3}$) and rs5355T allele in SELE associated with decreased diastolic blood pressure levels ($P_2=5 \times 10^{-3}$). Both variants interacted in order to influence blood pressure levels ($P_{G*E}=0.048$). This interaction was replicated with systolic blood pressure increase in 4,620 additional European individuals ($P_{G*E}=0.03$). Similarly, in this replication cohort, rs6046A was associated with decreased blood pressure levels ($P_3=8.5 \times 10^{-5}$). Furthermore, in peripheral blood mononuclear cells of a subsample of 90 supposed healthy individuals, we found rs6046A positively associated with NAMPT mRNA levels ($P_4=9.1 \times 10^{-4}$), suggesting an eventual involvement of NAMPT expression in blood pressure regulation. Confirming this hypothesis, further transcriptomic analyses showed that increased NAMPT mRNA levels were positively correlated with ICAM1, SEL, FPR1, DEFA1-3, and LL-37 genes expression ($P_5=5 \times 10^{-3}$). The last two mRNA levels were positively associated with systolic blood pressure levels ($P_6=0.01$) and explained 4% of its phenotypic variation.

Conclusion: These findings reveal the importance of epistatic interactions in blood pressure genetics and give new insights for the role of inflammation in its complex regulation.

Citation: El Shamieh S, Ndiaye NC, Stathopoulou MG, Murray HA, Masson C, et al. (2012) Functional Epistatic Interaction between rs6046G>A in F7 and rs5355C>T in SELE Modifies Systolic Blood Pressure Levels. PLoS ONE 7(7): e40777. doi:10.1371/journal.pone.0040777

Editor: Yong-Gang Yao, Kunming Institute of Zoology, Chinese Academy of Sciences, China

Received March 30, 2012; Accepted June 13, 2012; Published July 18, 2012

Copyright: © 2012 El Shamieh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This project was realized thanks to the Bio-Intelligence project. We also thank the “Institut national de la santé et de la recherche médicale” (INSERM), the “Région Lorraine”, the “communauté Urbaine de Grand Nancy” and the “Université de Lorraine” for supporting this work. Samples and data used for this study are part of the Biological Resources Center (BRC): “Interactions Gène-Environnement en Physiopathologie Cardio-Vasculaire” (IGE-PCV) in Nancy, France. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have read the journal’s policy and have the following conflicts: Helena A. Murray, John V. Lamont, and Peter Fitzgerald are affiliated with Randox Laboratories, Crumlin, United Kingdom. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.

* E-mail: Sophie.Visvikis-Siest@inserm.fr

Introduction

Blood pressure (BP) is a heritable trait with estimates indicating that 30–70% of its variance is attributed to genetics [1,2]. In family studies its heritability varies, according to measurement processes, from $\approx 31\%$ [single-measure of systolic blood pressure (SBP) and diastolic blood pressure (DBP),] to $\approx 57\%$ [long-term average of SBP and DBP phenotypes] and to $\approx 60\%$ [24-hour profile of SBP and DBP] [3]. Both BP and essential hypertension (HTN) are considered polygenic traits [4]. Inflammation, blood coagulation cascade, cellular adhesion molecules and lipid metabolism appear to have significant roles [5].

The largest Genome-wide association study (GWAS) on BP including $\approx 200,000$ individuals [6] reported 29 loci to be associated with SBP, DBP and/or essential HTN [6]. However, their genetic risk score explained only 0.9% of BP phenotypic variation [6], this representing the so-called ‘dark matter’ of genetic risk [7]. Despite the very large sample-size studies used for gene discovery, many common variants with small effects on BP may remain unidentified [8]. A large ‘hidden heritability’ of unknown nature may be explained by rare variants, structural large variants, epistatic [gene*gene (G*G)] and gene*environment (G*E) interactions [7]. We pointed out that epistatic interactions might also play an important role in discovering new genes [7]. This statement has been extensively reviewed in the last years and multi-locus methods have been developed to detect such interactions [7].

Epistatic interactions have been documented for susceptibility to cancer [9], morphology [10] and autoimmune conditions [11]. However, to date they have not been extensively studied in BP regulation. We hypothesize that the research of epistatic interactions among candidate single nucleotide polymorphisms (SNPs) represents a challenge in the investigation of disease-risk variants, as their application to high-dimensional genome-wide data...
exhaustively including all SNPs combinations is not yet feasible [7]. In previous candidate gene studies, we showed interesting results concerning the identification of BP candidate SNPs [12–16]. However, these studies were conducted in limited-sized populations.

Therefore, in the present study, we investigated BP epistasis mechanisms in a pre-planned two-phase approach gathering 8,220 European individuals. The effect of 10 candidate SNPs and then, G×G interactions between significant SNPs were assessed in a discovery population of 3,600 individuals. Highlighted epistases were replicated in 4,620 additional European individuals. We further searched for association(s) with 10 inflammation-related genes in peripheral blood mononuclear cells (PBMCs) (IL37, DEFA1-3, FPR1, ICAM1, SELP, SELP, NAMPT (visfatin), LEP, TNF and IL-6) [17] of a subsample of 90 supposed healthy individuals. Finally, we sought to propose a possible molecular mechanism of action.

Materials and Methods

Ethics Statement

All participants involved in the present study were recruited in accordance with the latest version of the Declaration of Helsinki for Ethical Principles for Medical Research Involving Human Subjects and gave written informed consent. Genetic studies protocols were approved by the local ethics committees for the protection of subjects for biomedical research: 1) the Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale de Lorraine, Nancy, France, for populations recruited in the Center of Preventive Medicine, 2) the Comité d’Ethique du Centre Hospitalier Universitaire de Cochin, Paris, France, for ERA population. 3) The ethic committee of Belfast, Ireland, for population recruited in Ireland.

Study Populations

Discovery population. A sample of 2,971 unrelated individuals was recruited during free medical check-ups at the Center of Preventive Medicine of Vandœuvre-lès-Nancy in the East of France. They were Caucasians, born in France for three generations and their clinical and biological data were collected at baseline before any eventual drug prescription following consultation. They were selected on the basis of the following criteria: (1) no antihypertensive drug therapy at recruitment; (2) complete clinical and genotypic data available; (3) BP levels ranging from normotensive to stage 2 HTN; and (4) only European origins were analyzed (Ireland, French). Stage 3 HTN patients were also excluded in the replication population as they were treated with antihypertensive medication.

Repliation population. We used a non-overlapping sample extracted from the BRC IGE-PCV. Altogether, 4,620 individuals with (1) no antihypertensive drug therapy at recruitment; (2) complete clinical and genotypic data for rs3553C>T in SELE and rs6046G>A in F7 were available; (3) BP levels ranging from normotensive to stage 2 HTN; and (4) only European origins were analyzed (Ireland, French). Stage 3 HTN patients were also excluded in the replication population as they were treated with antihypertensive medication.

Clinical and Biological Data Collection

SBP and DBP were measured under constant temperature (19°C–21°C) and standardized conditions (supine position) using a manual sphygmomanometer (Colonne à mercure, Mercurius) by expert nurses [18]. The recorded values were the means of 3 readings with 20 min intervals. An adjustable BP cuff was used to correct errors due to variations in arm circumference [19]. HTN was defined as SBP ≥140 mmHg or DBP ≥90 mmHg as recommended in the Seventh Report of the Joint National Committee on the prevention, detection, evaluation, and treatment of high BP [20]. All individuals underwent complete medical examination including anthropometric and biochemical measurements collected with standardized methods as described elsewhere [17].

Genotyping Assays

We selected rs1799752Ins del in ACE, rs5882A>G in CETP, rs1801133C>T in MTHFR rs662A>G in PON1 and rs1800629G>A in TNF from the “Cardio-Vascular Disease 35” assay, a multilocus genotyping assay developed in collaboration with Roche Molecular Systems [12]. These genetic variants were candidate markers for cardiovascular disease (CVD) risk factors, specifically involved in the predisposition to essential HTN (rs1799752Ins del in ACE), in the development of atherosclerotic plaques and in the progression of atherosclerosis (rs5882A>G in CETP, rs1801133C>T in MTHFR rs662A>G in PON1 and rs1800629G>A in TNF) [12]. In addition, rs5355C>T in SELE [13,21], rs1800790G>A in FGB [14], rs6046G>A in F7 [15], rs328C>G in LPL [16,22] were chose based on our previous published studies that found these SNPs associated with BP levels and/or HTN in European populations [12–16,21,22]. Finally, rs3025058T>Ins in MMP3 was selected from an internal investigation showing a link between this genetic variant and BP levels.

A summary of investigated genetic variants (nearby gene, location, type and mutation) was shown in Supplementary Data S1.

Genomic DNA was extracted from peripheral blood samples using the salting out method [23]. Genotyping was performed using two methods in the discovery population. 1) A multilocus assay with an immobilized probe approach designed by Roche Molecular Systems, Pleasanton, California, USA [24]. After PCR amplification using pooled biotinylated primers and hybridization to sequence-specific oligonucleotide probes, two independent observers using proprietary Roche Molecular Systems image processing software performed genotype assignments. Among 2,971 individuals, discordant results (<3% of all scoring) were resolved by a third observer and if necessary, by a joint reading. 2) Evidence Investigator™ biochip designed by Randox Laboratories, Antrim, UK was used to genotype ERA participants. This genotyping assay is based on a combination of probe hybridization, ligation, PCR amplification and microarray hybridization. This unique design permits high assay multiplexing and ready discrimination between genotypes. For the validation of genotyping results, blinded replication analysis was performed on 50
Results

Table 1 presents the clinical characteristics of the studied populations. According to the Seventh Report of the Joint National Committee [28], 21.8% of participants had normal BP, 32% were pre-hypertensive and 46.2% had HTN stage 1 and 2 in the discovery population (Table 1). In the replication set, 34% had normal BP, 39.8% were pre-hypertensive and 26.2% had HTN stage 1 and 2 (Table 1). A higher frequency of HTN was observed in the discovery compared to the replication population (46.2% vs. 26.2% respectively), which is partly due to the presence of older individuals in the discovery set.

Table 2 shows genetic variants associated with BP traits. We found two SNPs, rs5355C>T in SELE and rs6046G>A in F7 showing associations with SBP and/or DBP respectively in the replication population.

**Table 1. Characteristics of studied individuals.**

|                   | Discovery population             | Replication population            |
|-------------------|---------------------------------|----------------------------------|
| N (% women)       | 3,600 (47.4)                    | 4,620 (43.3)                     |
| Age (years)       | 47.3±10.5                       | 38.2±16.6                       |
| BMI (kg/m²)       | 25.4±3.8                        | 24.3±4.4                        |
| SBP (mmHg)        | 136.9±20.2                      | 130.6±20.1                      |
| DBP (mmHg)        | 84.1±13.8                       | 77.1±16                         |
| BP category (%)   |                                 |                                 |
| <120/80 mmHg      | 21.8                            | 34                              |
| 120–139/80–89 mmHg| 32                              | 39.8                            |
| ≥140 and/or 90 mmHg| 46.2                            | 26.2                            |
| MAF (%)           |                                 |                                 |
| rs5355C>T         | 16                              | 9                               |
| rs6046G>A         | 25                              | 25                              |

BMI: body mass index, BP: blood pressure, SBP: systolic blood pressure, DBP: diastolic blood pressure, MAF: minor allele frequency.

doi:10.1371/journal.pone.0040777.t001

**PolyPhen Analysis of Nonsynonymous SNPs**

The prediction of nonsynonymous SNPs possible impacts on their protein structures was performed using PolyPhen [25].

**Peripheral Blood Mononuclear Cells Collection**

Freshly drawn peripheral venous blood (10 ml) was collected into tubes containing EDTA (Vacutainer, Becton Dickinson) under fasting conditions. PBMCs were isolated by centrifuging on a density gradient of Ficoll as described previously and stored at -80°C until RNA extraction [26]. PBMCs bank with high recovery of lymphocytes (97.5%) was constituted as described elsewhere [26].

**RNA Extraction and qRT-PCR Analysis**

Using a microarray analysis [5]; we selected the top 10 inflammation-related genes (from a total of 182 genes) having a higher expression in PBMCs of hypertensive individuals when compared with normotensives. Total RNA was isolated from PBMCs by an automated isolation procedure (MagNa Pure LC instrument). mRNA quality and stability were carefully tested [26]. Quantitative real-time PCR (qRT-PCR) was performed using LightCycler instrument (Roche Diagnostics, Mannheim, Germany) with Master Plus SYBR Green I kit for all gene transcripts. SELE and F7 were not quantified, as they were not expressed. Specific primers were designed using Primer Premier 3.0 software (Supplementary Data S1). All experiments were carried out in duplicates in a total reaction volume of 20 μl containing 0.5 mM of each specific primer. Negative and internal controls were included. All mRNA levels were normalized to the mRNA levels of POL2RA. The specificity of all PCR products was further verified by electrophoresis on 10% polyacrylamide gel (data available on demand). The clinical characteristics of the studied subsample were presented in Supplementary Data S1.

**Statistical Analyses**

Statistical analyses were performed using the SPSS® statistical software version 19.0 (SPSS, Inc, Chicago, Illinois). Polymorphisms with MAF deviating from Hardy-Weinberg equilibrium (HWE) were excluded from individual analyses. In order to determine the effect of the 10 selected genetic variants on SBP and DBP assuming additive models using the common wild type as the reference group; age, gender and body mass index (BMI)-adjusted linear regressions were performed for individual association analyses. Due to multiple testing, the significance level was set at P=5×10^-3 in the discovery and replication populations.

**G^G interactions.** Two-locus additive epistasis was defined as significant statistical interaction between two SNPs [27] and was determined when significant interaction existed on a linear additive model adjusted for age, gender and BMI. Epistatic interactions were only tested between individually significant associated SNPs. In both populations, Bonferroni correction for multiple testing was applied. The significance level was set at P≤0.05.

**SNP-mRNA association analysis.** Linear regressions were performed to assess the effect of SNPs previously associated to SBP and/or DBP in the first stage of our analyses on mRNA levels. In epistatic conditions, an interaction term was introduced in the model. The significance level was set at P≤5×10^-3 due to multiple testing.

**Pearson’s correlation analyses.** Pearson’s correlation was used to test the correlation between all genes expression and NAMPT levels (values log-transformed). The significance level was set at P≤0.01 due to multiple testing.

**Linear regression analysis between genes expression and BP levels.** Linear regression models were used to further assess the association of SELE, FPR1, ICAM1, DEFA1-3 and LL-37 with mRNA levels with SBP and DBP after adjustment for age and gender. The significance level was set at P≤0.01 due to multiple testing.

**URLs**

Primer Premier 3.0 is available at: http://frodo.wi.mit.edu/primer3/.

Polyphen is available at: http://genetics.bwh.harvard.edu/pph2/.
discovery population ($P_{\text{discovery}} = 5 \times 10^{-3}$, Table 2). rs5355T allele in SELE was associated with decreased DBP levels ($P = 5 \times 10^{-3}$, $\beta = -0.04$, Table 2), whereas rs6046A allele in $F7$ was associated with decreased SBP and DBP levels respectively ($P = 3.7 \times 10^{-3}$ and $P = 8.2 \times 10^{-4}$ respectively, Table 2). Both SNPs are non synonymous, introducing amino acid substitutions (Leu575Phe and Arg553Gln respectively). According to Polyphen, they were predicted to have a null effect on their corresponding protein structures. Full individual association results with BP in the discovery and the replication population were shown in Supplementary Data S1.

In order to examine whether rs5355C>T in SELE and rs6046G>A in $F7$ may also indirectly influence BP levels, we tested their G*G interaction (Table 3). Both SNPs interacted in order to influence SBP levels, resulting an increase in SBP mean (5.1 mmHg and 3.8 mmHg increase in SBP respectively when compared to carriers of rs5355C allele in SELE. We found that individuals carrying rs5355T allele in SELE and rs6046G in $F7$ had 6.5 mmHg and 0 mmHg decrease in SBP and DBP respectively when compared with carriers of rs3555C allele in SELE and rs6046G genotype in $F7$ (Table 3). In contrast, individuals carrying rs5355T allele in SELE and one minor allele of rs6046G (rs6046GA) had 5.1 mmHg and 1.2 mmHg increase in SBP and DBP respectively when compared with carriers of rs3555C allele in SELE, rs6046GA genotype in $F7$ (Table 3A). Furthermore, carriers of rs3555T allele in SELE and two minor alleles of rs6046G>A (rs6046AA) had higher BP levels when compared with those carrying rs5355C allele in SELE and rs6046AA genotype in $F7$ (5.1 mmHg and 3.8 mmHg increase in SBP and DBP respectively) (Table 3A). We concluded that rs6046A might invert the BP-lowering effect of rs5355T on DBP and SBP.

In the replication population, rs6046G>A in $F7$ was also associated with decreased SBP ($P_{\text{replication}} = 8.45 \times 10^{-4}$ and $P_{\text{meta}} = 2.03 \times 10^{-4}$) and DBP ($P_{\text{replication}} = 2.58 \times 10^{-7}$ and $P_{\text{meta}} = 9.16 \times 10^{-4}$). In contrast, rs3555C>T was not associated with DBP ($P_{\text{replication}} = 0.96$). Most importantly, we found rs5355C>T in SELE and rs6046G>A in $F7$ interacting in order to influence the SBP ($P_{\text{replication}} = 0.03$, Table 3B). Similar SBP variations according to rs5355T allele in SELE and rs6046G/A genotypes in $F7$ were successfully found (Table 3B).

In conclusion, rs5355C>T in SELE interacted with rs6046G>A in $F7$ in order to influence SBP in a total of 8,220 European individuals.

We investigated the eventual relation(s) between the epistatic interaction and the inflammation-related genes in a PBMCs model. rs5355C>T in SELE was not associated with any of the investigated transcripts. In contrast, rs6046A allele in $F7$ was positively associated with NAMPT mRNA levels in both models (individual association and epistatic interaction models ($P = 9.2 \times 10^{-5}$, $\beta = 0.493$ and $P = 1.1 \times 10^{-5}$, $\beta = 0.352$ respectively).

Increased NAMPT mRNA levels were positively correlated with ICAM1 ($P < 1 \times 10^{-4}$ and $\beta = 0.576$, Table 4), SELL ($P = 5 \times 10^{-3}$ and $r = 0.308$, Table 4), FPR1 ($P = 2 \times 10^{-4}$ and $r = 0.394$, Table 4), LL-37 ($P = 4 \times 10^{-4}$ and $r = 0.452$, Table 4) and DEFA-1 ($P = 5 \times 10^{-4}$ and $r = 0.28$, Table 4) genes expression. In addition ICAM1, SELL, FPR1 and DEFA-1 expressions were also correlated ($P < 5 \times 10^{-3}$, Table 4). Only DEFA-1 and LL-37 mRNA levels were positively associated with SBP. We found that both mRNAs explained 4% of SBP phenotypic variation ($P = 3 \times 10^{-3}$, $\beta = 0.04$ and $P = 0.01$, $\beta = 0.03$ respectively).

**Discussion**

In the current study, we found rs6046A allele in $F7$ associated with decreased BP levels ($P = 3.7 \times 10^{-3}$ and $P_{\text{meta}} = 2.03 \times 10^{-4}$). In the discovery cohort, rs5355T allele in SELE was also associated with decreased DBP ($P = 5 \times 10^{-3}$).

rs6046G>A in $F7$ was shown to be associated with increased $F7$ plasma levels [15]. More interestingly, this SNP was reported to have a role in protection against myocardial infarction in two different studies performed on Italian populations [29,30]. rs5355C>T in SELE is located in chr1q, a genomic region linked to BP related phenotypes in two independent linkage studies [31,32]. These findings were supported by observation of mouse and rat BP-related quantitative trait loci in regions homologous to the human 1q chromosomal locus [33].

Herein, we showed that in a total of 8,220 European individuals, rs5355C>T in SELE interacted with rs6046G>A in $F7$ and the latter SNP in order to alter SBP ($P_{\text{discovery}} = 0.047$ and $P_{\text{replication}} = 0.03$ respectively, Table 3). The above interaction was differently associated with SBP variations according to rs6046G>A genotypes (Table 3). In fact, epistatic interactions are phenomena where the effect of a gene is modified by another one [34,35], thus although rs6046A allele in $F7$ was associated with decreased BP levels, it interacted with rs5355T allele in SELE in order to influence SBP levels, resulting an increase in SBP mean values.

The non-replication of the association between rs5355C>T in SELE and DBP is not surprising as insignificant interaction effect on DBP between these two variants was found in the replication cohort. It is important to point out that, it has been postulated that epistatic interactions may identify genetic markers that are not captured by individual marker analysis and/or revealed by the combinatory effect of loci in other pathways [34,35].

**Table 2. Genetic variants associated with blood pressure.**

| Chr | Gene | SNP ID | Discovery population | Replication population | $P_{\text{meta}}$ | BP trait |
|-----|------|--------|----------------------|------------------------|------------------|---------|
| 1q22-q25 | SELE | rs5355C>T | $5 \times 10^{-3}$ | $-0.04$ | 0.86 | DBP |
| 1q34 | $F7$ | rs6046G>A | $3.7 \times 10^{-4}$ | $-0.06$ | $8.45 \times 10^{-4}$ | $-0.03$ | SBP |
| | | | $8.2 \times 10^{-4}$ | $-0.08$ | $2.58 \times 10^{-7}$ | $-0.03$ | 9.16 $\times 10^{-4}$ | DBP |

* Log10 transformed values.
Beta coefficients are shown for significant associations.
Chr: chromosome, SNP: single nucleotide polymorphism, MAF: minor allele frequency, Beta: coefficient in the linear regression model, BP: blood pressure, $P_{\text{meta}}$: P meta-analysis, SBP: systolic blood pressure, DBP: diastolic blood pressure.

doi:10.1371/journal.pone.0040777.t002
postulate might explain why the two variants investigated here (and many others) were not reported among the top GWAS SNPs.

It was proven that blood coagulation factors enhance the inflammatory response leading to endothelial dysfunction accounting in part, for the vascular complications occurring in CVDs and their risk factors [36]. Thus, we searched for eventual relation(s) between the epistatic interaction and the inflammation-related genes expression. rs6046A allele in F7 with the inflammation-related genes expression, rs6046A allele in F7 was associated with increased NAMPT mRNA levels (P=9.2×10⁻⁴). NAMPT levels were also positively correlated with ICAM1, SELL, FPR1, DEFA1-3 and LL-37 genes expression (P≤5×10⁻³, Table 4). In addition ICAM1, SELL, FPR1 and DEFA1-3 expressions were also correlated (P≤5×10⁻³, Table 4).

Table 3. Blood pressure variations according to rs5355T allele in SELE and rs6046G/A genotypes in F7 when compared to rs5355C allele in SELE.

| A-Discovery population | SELE | rs5355T | p* | rs5355T | p* |
|------------------------|------|---------|----|---------|----|
|                        |      | SBP (mmHg) |   | DBP (mmHg) |   |
| F7                     |      |           |    |           |    |
| rs6046GG               | −6.5 | rs6046GG | −8 |
| rs6046GA               |  6.1 | 0.047    |  1.2 | 0.048   |
| rs6046AA               |  5.1 |         |  3.8 |

| B-Replication population | SELE | rs5355T | p* | rs5355T | p* |
|--------------------------|------|---------|----|---------|----|
|                         |      | SBP (mmHg) |   | DBP (mmHg) |   |
| F7                      |      |           |    |           |    |
| rs6046GG                | −6.5 | rs6046GG | −   |
| rs6046GA                |  2.2 | 0.03     |  − | 0.102   |
| rs6046AA                |  3   |         |  − |

Only significant blood pressure variations are shown. BP variations in individuals carrying rs5355T allele in SELE and rs6046GG in F7 were compared with carriers of rs5355C allele in SELE and rs6046GA genotype in F7. BP variations in individuals carrying rs5355T allele in SELE and rs6046GA genotype in F7 were compared with carriers of rs5355C allele in SELE, rs6046GA genotype in F7. BP variations in carriers of rs5355T allele in SELE and rs6046AA genotype in F7 were compared with those carrying rs5355C allele in SELE and rs6046AA genotype in F7.

Table 4. Pearson’s correlations between NAMPT, ICAM1, SELL, FPR1, DEFA1-3 and LL-37 genes expression.

| r   | P     | NAMPT | ICAM1 | SELL | FPR1 | DEFA1-3 | LL-37 |
|-----|-------|-------|-------|------|------|---------|-------|
| NAMPT|  0.6  |  0.3  |  0.4  |  0.3 |  0.5 |         |       |
| ICAM1|<1×10⁻⁴|       |  0.5  |  0.6 |  0.3 |         |  0.4  |
| SELL | 5×10⁻³|<1×10⁻⁴|  0.697|       | −    |         |       |
| FPR1 | 2×10⁻⁴|<1×10⁻⁴|<1×10⁻⁴|       | −    |         |  0.3  |
| DEFA1-3|5×10⁻³| 5×10⁻³|  −    |  −   |  −   |         |  0.9  |
| LL-37| 4×10⁻³| 1×10⁻³| <1×10⁻⁴|<1×10⁻⁴|       |         |       |

Only Significant correlations are shown (P≤5×10⁻³). All genes expression were normalized to POL2R4A mRNA levels. r: Pearson’s correlation coefficient, P: P-value.

doi:10.1371/journal.pone.0040777.t004

Physiologically relevant data concerning many health related traits [39]. The role of multiple metabolic pathways in HTN makes the study of PBMCs transcriptome important for the possible developing of diagnostic and prognostic tests [40], we assessed associations between rs5355C>T in SELE and rs6046G>A in F7 with the inflammation-related genes expression, rs6046A allele in F7 was associated with increased NAMPT mRNA levels (P≤9.2×10⁻⁴). NAMPT levels were also positively correlated with ICAM1, SELL, FPR1, DEFA1-3 and LL-37 genes expression (P≤5×10⁻³, Table 4). In addition ICAM1, SELL, FPR1 and DEFA1-3 expressions were also correlated (P≤5×10⁻³, Table 4).

Only DEFA1-3 and LL-37 expressions were associated with SBP (P=3×10⁻³ and P=0.01 respectively) and explained 4% of its variation. Therefore, we suggest that the associations of DEFA1-3 and LL-37 mRNAs and SBP reflect the epistatic interaction and not the main effect of rs6046G>A in F7. Visfatin is a multifunctional protein that has been reported to be involved in innate immune system [41] and several other biological processes such as the cardiovascular system [42]. However, its role in BP was unclear. Supporting our results, three different in vitro studies have demonstrated that visfatin induced an endothelial dysfunction by increasing inflammatory and adhesion molecules expression such as ICAM1 [43–45]. In addition, in a previous study we have reported that gene expression of an antimicrobial peptide LL-37 in PBMCs was associated with altered BP levels [46]. The above findings support our epistatic and the in vivo results revealing an indirect link between NAMPT gene expression and BP through the expression of adhesion and innate immune system molecules.

Strengths and Limitations

The genetics of BP has never been easy [47]. For many years, it has been dominated by the stark contrast between its high heritability and the frustrating reality that no clearly reproducible and functional genetic variant could be discovered [3], with epistatic interactions accepted as cause of discrepancies across the studies.
The current study shows the first replicated epistatic interaction in the BP genetics field. This interaction between a coagulation factor gene (F7) and an adhesion molecule gene (SELE) is putatively functional through its link with five inflammation-related gene expression. Going in the same direction; it has been demonstrated that some blood coagulation factors can induce an endothelial dysfunction (SELE is a marker of endothelial dysfunction) through an inflammatory response accounting for the vascular complications occurring in CVDs and their risk factors [36]. Similarly, NAMPT expression was shown to increase the expression of inflammatory and adhesion molecules such as ICAM1, SELL, FPR1 and DEFA1-3 genes expression. Only DEFA1-3 and LL-37 expressions were correlated and associated with SBP levels and explained 4% of its variation.

doi:10.1371/journal.pone.0040777.g001

Figure 1. Summary of the study and hypothesis for rs5355C>T in SELE and rs6046G>A in F7 interaction. rs6046A allele in F7 was associated with decreased BP levels. rs5355C>T in SELE and rs6046G>A in F7 interacted in order to alter SBP levels, rs6046A inverted the BP-lowering effect of rs5355T. rs6046A allele in F7 was positively associated with increased NAMPT gene expression. NAMPT levels were positively correlated with ICAM1, SELL, FPR1 and DEFA1-3 genes expression. Only DEFA1-3 and LL-37 expressions were correlated and associated with SBP levels and explained 4% of its variation.

Conclusion

Our findings are summarized in Figure 1. In European populations, we confirmed that rs6046A in F7 is associated with decreased BP. Furthermore, we found that rs5355C>T in SELE and rs6046G>A in F7 interacted in order to alter SBP levels. In addition rs6046A allele in F7 was positively associated with increased NAMPT gene expression, which was linked with BP through inflammatory mechanisms via the expression of adhesion and innate immune system molecules.

Perspectives

Even if additional investigations are needed, the present study highlighted the importance of taking into account candidate genes, GWAS and epistatic interactions in order to deep investigate BP genetic regulation. One must also consider the functionality of relationships and G*E interactions that might be at the origin of the low until now predictive values of results in HTN. This integrative approach could better explain the missing heritability of this complex trait.

Supporting Information

Supplementary Data S1 (DOC)
Author Contributions
Conceived and designed the experiments: SES SVS. Performed the experiments: SES HAM CM. Analyzed the data: NCM MGS SES SVS. Contributed reagents/materials/analysis tools: PF JVL. Wrote the paper: Ehet GB (2010) Genome-wide association studies: contribution of genomics to understanding blood pressure and essential hypertension. Curr Hypertens Rep 12: 17–25.

Levy D, DeStefano AL, Larson MG, O'Donnell CJ, Lifton RP, et al. (2000) Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study. Hypertension 36: 477–483.

Visvikis-Siest S, Marteau JB, Samara A, Berrahmoune H, Marie B, et al. (2007) Peripheral blood mononuclear cells (PBMCs): a possible model for studying cardiovascular biology systems. Clin Chem Lab Med 45: 1134–1140.

Ehet GB, Monroe PB, Rice KM, Bockhod, J. 2010. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478: 105–109.

Nutt AE, Anami N, El Shami, S. Staphylococcus MG, Visvikis-Siest S (2011) Cardiovascular diseases and genome-wide association studies. Clin Chem Lab Med 41A: 1697–1715.

Taal HR, Verwoert GC, Demirkic A, Janssen AC, Rice K, et al. (2011) Genome-Wide Profiling of Blood Pressure in Adults and Children. Hypertension. HYPERTENSIONAHA.111.179481.

Fijneman RJ, de Vries SS, Janssen RC, Deman P (1996) Complex interactions of new quantitative trait loci, Sac1, Sac2, Shuc3, and Shuc7, that influence the susceptibility to lung cancer in the mouse. Nat Genet 14: 465–467.

Leamy IJ, Routman EJ, Cheverud JM (2002) An epistatic genetic basis for fluctuating asymmetry of mandible size in mice. Evolution 56: 642–653.

Wanders RA, Wieland F. (2001) The genes of complex autoimmunity diseases: non-MHC susceptibility genes. Nat Immunol 2: 892–899.

Cheng S, Grow MA, Pallad C, Klitz W, Erlich HA, et al. (1999) A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 9: 936–949.

Marteau JB, Sas C, Piffer M, Lambeth D, Noyer-Weidner M, et al. (2004) The Leu554Phe polymorphism in the E-selectin gene is associated with blood pressure in overweight people. J Hypertens 22: 305–311.

Maumus S, Marie B, Vincent-Viry M, Siest G, Visvikis-Siest S (2007) Analysis of the effect of multiple genetic variants of cardiovascular disease risk on insulin concentration variability in healthy adults of the STANISLAS cohort. The role of FGF-15/Ga4/apolipoprotein. Atherosclerosis 191: 569–576.

Seo C, Blangy A, Morange PE, Piffer M, Visvikis-Siest S (2004) Association between factor VII polymorphisms and blood pressure: the Stanislas Cohort. Hypertension 44: 674–680. doi: 10.1161/01.HYP.0000143595.25151.7a.

Winkler BA, Wieland F. (2001) The genes of complex autoimmunity diseases: non-MHC susceptibility genes. Nat Immunol 2: 892–899.

Cheng S, Grod MA, Pallad C, Klitz W, Erlich HA, et al. (1999) A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 9: 936–949.

Marteau JB, Sas C, Piffer M, Lambeth D, Noyer-Weidner M, et al. (2004) The Leu554Phe polymorphism in the E-selectin gene is associated with blood pressure in overweight people. J Hypertens 22: 305–311.

Maumus S, Marie B, Vincent-Viry M, Siest G, Visvikis-Siest S (2007) Analysis of the effect of multiple genetic variants of cardiovascular disease risk on insulin concentration variability in healthy adults of the STANISLAS cohort. The role of FGF-15/Ga4/apolipoprotein. Atherosclerosis 191: 569–576.

Seo C, Blangy A, Morange PE, Piffer M, Visvikis-Siest S (2004) Association between factor VII polymorphisms and blood pressure: the Stanislas Cohort. Hypertension 44: 674–680. doi: 10.1161/01.HYP.0000143595.25151.7a.

Winkler BA, Wieland F. (2001) The genes of complex autoimmunity diseases: non-MHC susceptibility genes. Nat Immunol 2: 892–899.

Cheng S, Grod MA, Pallad C, Klitz W, Erlich HA, et al. (1999) A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 9: 936–949.

Marteau JB, Sas C, Piffer M, Lambeth D, Noyer-Weidner M, et al. (2004) The Leu554Phe polymorphism in the E-selectin gene is associated with blood pressure in overweight people. J Hypertens 22: 305–311.

Maumus S, Marie B, Vincent-Viry M, Siest G, Visvikis-Siest S (2007) Analysis of the effect of multiple genetic variants of cardiovascular disease risk on insulin concentration variability in healthy adults of the STANISLAS cohort. The role of FGF-15/Ga4/apolipoprotein. Atherosclerosis 191: 569–576.

Seo C, Blangy A, Morange PE, Piffer M, Visvikis-Siest S (2004) Association between factor VII polymorphisms and blood pressure: the Stanislas Cohort. Hypertension 44: 674–680. doi: 10.1161/01.HYP.0000143595.25151.7a.

Winkler BA, Wieland F. (2001) The genes of complex autoimmunity diseases: non-MHC susceptibility genes. Nat Immunol 2: 892–899.

Cheng S, Grod MA, Pallad C, Klitz W, Erlich HA, et al. (1999) A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 9: 936–949.

Marteau JB, Sas C, Piffer M, Lambeth D, Noyer-Weidner M, et al. (2004) The Leu554Phe polymorphism in the E-selectin gene is associated with blood pressure in overweight people. J Hypertens 22: 305–311.

Maumus S, Marie B, Vincent-Viry M, Siest G, Visvikis-Siest S (2007) Analysis of the effect of multiple genetic variants of cardiovascular disease risk on insulin concentration variability in healthy adults of the STANISLAS cohort. The role of FGF-15/Ga4/apolipoprotein. Atherosclerosis 191: 569–576.

Seo C, Blangy A, Morange PE, Piffer M, Visvikis-Siest S (2004) Association between factor VII polymorphisms and blood pressure: the Stanislas Cohort. Hypertension 44: 674–680. doi: 10.1161/01.HYP.0000143595.25151.7a.

Winkler BA, Wieland F. (2001) The genes of complex autoimmunity diseases: non-MHC susceptibility genes. Nat Immunol 2: 892–899.

Cheng S, Grod MA, Pallad C, Klitz W, Erlich HA, et al. (1999) A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 9: 936–949.